Emergent BioSolutions (EBS) Non-Current Debt: 2010-2025
Historic Non-Current Debt for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $663.1 million.
- Emergent BioSolutions' Non-Current Debt rose 0.20% to $663.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $663.1 million, marking a year-over-year increase of 0.20%. This contributed to the annual value of $663.7 million for FY2024, which is 48.65% up from last year.
- Latest data reveals that Emergent BioSolutions reported Non-Current Debt of $663.1 million as of Q3 2025, which was down 0.70% from $667.8 million recorded in Q2 2025.
- In the past 5 years, Emergent BioSolutions' Non-Current Debt ranged from a high of $1.0 billion in Q3 2022 and a low of $446.5 million during Q4 2023.
- Its 3-year average for Non-Current Debt is $546.0 million, with a median of $448.2 million in 2023.
- In the last 5 years, Emergent BioSolutions' Non-Current Debt crashed by 56.57% in 2023 and then soared by 49.40% in 2025.
- Emergent BioSolutions' Non-Current Debt (Quarterly) stood at $809.4 million in 2021, then plummeted by 44.59% to $448.5 million in 2022, then fell by 0.45% to $446.5 million in 2023, then surged by 48.65% to $663.7 million in 2024, then increased by 0.20% to $663.1 million in 2025.
- Its Non-Current Debt stands at $663.1 million for Q3 2025, versus $667.8 million for Q2 2025 and $665.7 million for Q1 2025.